From the Journals

GLP-1–Progestin and Endometrial Cancer Risk

Adjunct therapy tied to fewer cancers and hysterectomies.

Share

A recent retrospective cohort study published in JAMA Network Open by Dr. Ting-Tai Yen and colleagues from Texas Tech University Health Sciences Center El Paso indicates that adding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to progestin therapy may significantly lower the risk of endometrial cancer in women with benign uterine diseases or hyperplasia. The analysis of health records from over 400,000 women revealed that this combination therapy not only reduced cancer risk but also decreased the need for hysterectomy, highlighting the importance of novel therapeutic strategies to mitigate hormonal and metabolic risks associated with increasing endometrial cancer rates, particularly in women with obesity and metabolic disorders.

Original Source(s)

GLP-1–Progestin and Endometrial Cancer Risk

Adjunct therapy tied to fewer cancers and hysterectomies.

  • by Julia Cipriano, MS, CMPP

  • March 2, 2026

  • 3 min

Related Content

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk

Exercise Matters Following Cancer

Postdiagnosis physical activity was associated with lower cancer mortality across several cancer types.

FDA Approves Device for Pancreas Care

In the phase 3 PANOVA-3 trial, adding Tumor Treating Fields therapy to gemcitabine and nab-paclitaxel was associated with improved overall survival and delayed pain progression in adults with locally advanced pancreatic cancer.